Brief report novel mechanism for valproate-induced teratogenicity

Birth Defects Research Part A - Clinical and Molecular Teratology

Volumn 100, Issue 8, 2014, Pages 592-597

  Fathe, Kristin ^a   Palacios, Ana ^b   Finnell, Richard H ^b  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Birth defects; Folate; Teratogens; Valproic acid; Vitamin transport

Indexed keywords

FOLATE RECEPTOR; FOLATE RECEPTOR 1; FOLIC ACID; VALPROIC ACID; PROTEIN BINDING; TERATOGENIC AGENT; VITAMIN B COMPLEX;

ARTICLE; BINDING AFFINITY; BIOAVAILABILITY; CELL DEATH; CELL SURFACE; CONTROLLED STUDY; EMBRYO DEVELOPMENT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEK293 CELL LINE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MOTHER; PRIORITY JOURNAL; RECEPTOR BINDING; TERATOGENICITY; UPREGULATION; ANTAGONISTS AND INHIBITORS; CELL LINE; CHEMICALLY INDUCED; DRUG EFFECTS; DRUG INDUCED MALFORMATION; METABOLISM; NEURAL TUBE DEFECT; PREGNANCY;

ABNORMALITIES, DRUG-INDUCED; BIOLOGICAL AVAILABILITY; CELL LINE; EMBRYONIC DEVELOPMENT; FEMALE; FOLATE RECEPTORS, GPI-ANCHORED; FOLIC ACID; HEK293 CELLS; HUMANS; NEURAL TUBE DEFECTS; PREGNANCY; PROTEIN BINDING; TERATOGENS; VALPROIC ACID; VITAMIN B COMPLEX;

EID: 84906499119     PISSN: 15420752     EISSN: 15420760     Source Type: Journal    
DOI: 10.1002/bdra.23277     Document Type: Article

References (31)

1. Alonso-Aperte E, Varela-Moreiras G. 2000. Drugs-nutrient interactions: a potential problem during adolescence. Eur J Clin Nutr 54:S69-S74.
2. Bandara NA, Hansen MJ, Low PS. 2014. Effect of receptor occupancy on folate receptor internalization. Mol Pharm 11:1007-1013.
3. Blom HJ, Shaw GM, den Heijer M, Finnell RH. 2006. Neural tube defects and folate: case far from closed. Nat Rev Neurosci 7:724-731.
4. Boshnjaku V, Shim KW, Tsurubuchi T, et al. 2012. Nuclear localization of folate receptor alpha: a new role as a transcription factor. Sci Rep 2:980.
5. Cabrera RM, Shaw GM, Ballard JL, et al. 2008. Autoantibodies to folate receptor during pregnancy and neural tube defect risk. J Reprod Immunol 79:85-92.
6. Committee on Genetics. 1999. Folic acid for the prevention of neural tube defects. Pediatrics 104:325-327.
7. Crudup JB, Hartley BI, Keel BR, et al. 2011. Recognizing and treating valproic acid toxicity: a case report. J Med Cases 5:185-187.
8. DiLiberti JH, Farndon PA, Dennis NR, Curry CJ. 1984. The fetal valproate syndrome. Am J Med Genet 19:473-481.
9. Elmazar, MM, Nau, H. 1993. Trimethoprim potentiates valproic acid-induced neural tube defects in mice. Reprod Toxicol 7:249-254.
10. Hill DS, Wlodarczyk BJ, Palacios AM, Finnell RH. 2010. Teratogenic effects of antiepileptic drugs. Expert Rev Neurother 10:943-959.
11. Hsieh CL, Wang HE Tsai WJ, et al. 2012. Multiple point action mechanism of valproic acid-teratogenicity alleviated by folic acid, vitamin C, and N-acetylcysteine in chicken embryo model. Toxicology 291:32-42.
12. Ibarra M, Vazquez M, Faqiolino P, Derendorf H. 2013. Sex related differences on valproic acid pharmacokinetics after oral single dose. J Pharmacokinet Pharmacodyn 40:479-486.
13. Jentink J, Loane MA, Dolk H, et al. 2010a. Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med 362:2185-2193.
14. Jentink J, Bakker MK, Nijenhuis CM, et al. 2010b. Does folic acid use decrease the risk for spina bifida after in utero exposure to valproic acid? Pharmacoepidemiol Drug Saf 19:803-807.
15. Kamen B, Smith AK. 2004. A review of folate receptor alpha cycling and 5-methyltetrahydrofolate accumulation with an emphasis on cell models in vitro. Adv Drug Deliv Rev 56:1085-1097.
16. Lammer EJ, Sever LE, Oakley GP. 1987. Teratogen update: valproic acid. Teratology 35:465-473.
17. Leamon CP, Low PS. 1993. Membrane folate-binding proteins are responsible for folate-protein conjugate endocytosis into cultured cells. Biochem J 291:855-860.
18. Meek MF, Broekroelofs J, Yska JP, et al. 2004. Valproic acid intoxication: sense and non-sense of haemodialysis. Neth J Med 62:333-336.
19. Ornoy A. 2009. Valproic acid in pregnancy: how much are we endangering the embryo and fetus? Reprod Toxicol 28:1-20.
20. Padmanabhan R, Shafiullah MM. 2003. Amelioration of sodium valproate-induced neural tube defects in mouse fetuses by maternal folic acid supplementation during gestation. Congenit Anom (Kyoto) 43:29-40.
21. Reynolds EH. 1973. Anticonvulsants, folic acid, and epilepsy. Lancet 1:1376-1378.
22. Rosenberg G. 2007. The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees? Cell Mol Life Sci 64:2090-2103.
23. Schwaninger M, Ringleb P, Winter R, et al. 1999. Elevated plasma concentrations of homocysteine in antiepileptic drug treatment. Epilepsia 40:345-350.
24. Sega EI, Low PS. 2008. Tumor detection using folate receptor-targeted imaging agents. Cancer Metastasis Rev 27:655-664.
25. Silva MF, Aires CC, Luis PB, et al. 2008. Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review. J Inherit Metab Dis 31:205-216.
26. Smith J, Whitehall J. 2009. Sodium valproate and the fetus: a case study and review of the literature. J Neonatal Nursing 28:363-367.
27. Smithells RW, Sheppard S, Schorach CJ, et al. 1980. Possible prevention of neural-tube defects by periconceptional vitamin supplementation. Lancet 315:339-340.
28. Solanky N, Requena Jimenez A, D'Souza SW, et al. 2010 Expression of folate transporters in human placenta and implications for homocysteine metabolism. Placenta 31:134-143.
29. Umur AS, Selcuki M, Bursali A, et al. 2012. Simultaneous folate intake may prevent adverse effect of valproic acid on neurulating nervous system. Childs Nerv Syst 28:729-737.
30. Whitsel A, Johnson CB, Forehand CJ. 2002. An in ovo chicken model to study the systemic and localized teratogenic effects of valproic acid. Teratology 66:153-63.
31. Yang J, Chen H, Vlahov IR, et al. 2007. Characterization of the pH of folate receptor-containing endosomes and the rate of hydrolysis of internalized acid-labile folate-drug conjugates. J Pharmacol Exp Ther 321:462-468.